Glut1 localization (patient)

Stray proteins cause genetic disorders

A tiny change in the very flexible segments of some proteins is enough to trigger rare disorders such as Glut1 deficiency syndrome. A study published in Cell found that other genetic disorders might be traced back to the same origin.

The seizures typically begin in the first months of life. It often takes years, however, before those suffering from the rare glucose transporter type 1 (Glut1) deficiency syndrome obtain a correct diagnosis. If the disorder goes untreated, affected children experience developmental delay and frequently have neurological problems. Various defects in one gene underlie the syndrome. They cause the Glut1 protein to lose its function in the cell membrane: the protein no longer transports glucose from the blood into the brain.

We have identified a promising target with considerable potential for developing new medications
Matthias Selbach group leader of the “Proteome Dynamics” lab

Miniscule changes in previously little-noticed flexible segments of the Glut1 protein could lead to severe cellular disturbances – other genetic disorders might be caused by the same mechanism. These are the findings of a study led by Professor Matthias Selbach of the Max Delbrück Center for Molecular Medicine (MDC) and published in the current issue of the journal Cell.

A fundamental problem

Selbach’s team wanted to answer a basic question: How do defective genes cause diseases? Within the Glut1 gene there are many places where a mutation can disrupt the Glut1 protein’s three-dimensional structure, leading to loss of function. Malformed and contorted, the protein can no longer carry out its task in the cellular machinery and thus triggers the syndrome. The same process is at work in most genetically determined disorders. “But the mechanism involved in genetically determined diseases – or, in other words, the cause at the molecular level – is often unclear,” says Katrina Meyer, a doctoral student in Selbach’s lab.

In one-fifth of all genetic diseases, according to the scientist, the protein structure doesn’t appear to be damaged at all. In such cases, she says, the mutation occurs in flexible loops in the proteins, which until recently were thought to have no function because they lack a defined structure. But appearances can be deceiving: “These so-called intrinsically disordered regions (IDRs) can snuggle up to other proteins as if they were soft pillows, thereby manipulate them.”

Katrina Meyer is punching samples from a membrane with artificial protein fragments

Many cellular processes are based on such interactions between proteins. The molecules interlock with each other like cogs, transfer energy, or move levers and conveyor belt systems. Even a single protein in the wrong place can have drastic consequences. Meyer therefore began by looking into which of the cell’s proteins come into contact with flexible mutated protein regions.

Subtle change with a big impact

The doctoral student did this by recreating 258 flexible protein regions in test tubes – both “healthy” variants as well as disease-related ones – and then adding human cell extracts. The next step involved using mass spectrometry to determine which proteins interact with the artificial proteins.

In Meyer’s experiment the mutated and “healthy” regions mostly docked onto the same binding partners. But some of the mutated proteins completely lost this ability or bound to other proteins and thus disrupted the operation of the cellular machinery. Some genetic changes even affect intracellular protein transport through this process. An example is a mutation in the gene for the Glut1 protein that causes two specific building blocks of protein, namely leucines,  to lie next to one another, creating a so-called dileucine motif. “This pattern is known to attract proteins that aid the cell in transporting other proteins inside its interior,” says Meyer.

The Glut1 protein molecules (green) appear mainly in the interior of the induced pluripotent stem cells derived from a patient

Right protein, wrong place

It was a special moment when Meyer made this discovery. Could it be that in people affected by this mutation the Glut1 protein is not defective but has instead ended up in the wrong place in the cell? “If the protein itself is not affected but only the transport function, there is a chance that the underlying cause can be treated – not just the symptom,” explains Meyer. She searched databases and found a patient with Glut1 deficiency syndrome in whom the protein region contained a mutation creating the dileucine motif. The patient donated cells to her. In tests on cell cultures Meyer showed that the mutated Glut1 protein was no longer present on the cell surface, where it takes up glucose. The protein was instead in the cell’s interior as if it had gotten lost.

Usually the Glut1 protein (green) resides in the cell’s membrane. Credit: Katrina Meyer, MDC

The cellular apparatus involved in pinching off vesicles from the cell membranes and transporting them into the cell’s interior via endocytosis is partially responsible for misrouting the Glut1 protein. Meyer was able to confirm her hypothesis: When she blocked this process, the Glut1 protein found its way back to the cell surface and resumed glucose uptake. “This could theoretically be blocked by medications,” says Meyer.

A new mechanism for numerous diseases

These medications don’t exist yet, says Matthias Selbach, head of the laboratory, but the discovery has implications beyond Glut1. By searching databases, the research team found the dileucine motif eleven times in the flexible regions of eight proteins, including in the protein that triggers the metabolic disorder cystic fibrosis.

“We have identified a promising target against a wide range of diseases,” says Selbach. “I see considerable potential here for developing new medications.” Future studies will need to determine whether these diseases can be systematically fought with endocytosis blockers.

Even though it often takes years for people affected by Glut1 deficiency syndrome to be correctly diagnosed, says Selbach, it is now relatively well treatable. Pasta, bread, and ice cream, however, are off limits to patients. They must follow a strict ketogenic diet, which involves avoiding foods that contain sugar and starch. Such a regimen usually causes the seizures to stop because the brain cells receive their energy from a different source. “But the disorder remains incurable,” says Selbach. “And patients must drastically restrict their diet.”

Literature

Katrina Meyer, et al. (2018): “Mutations in disordered regions can cause disease by creating dileucine motifs.” Cell. doi:10.1016/j.cell.2018.08.019

The Max Delbrück Center for Molecular Medicine (MDC)

 

The Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) was founded in Berlin in 1992. It is named for the German-American physicist Max Delbrück, who was awarded the 1969 Nobel Prize in Physiology and Medicine. The MDC's mission is to study molecular mechanisms in order to understand the origins of disease and thus be able to diagnose, prevent and fight it better and more effectively. In these efforts the MDC cooperates with the Charité - Universitätsmedizin Berlin and the Berlin Institute of Health (BIH) as well as with national partners such as the German Center for Cardiovascular Research and numerous international research institutions. More than 1,600 staff and guests from nearly 60 countries work at the MDC, just under 1,300 of them in scientific research. The MDC is funded by the German Federal Ministry of Education and Research (90 percent) and the State of Berlin (10 percent), and is a member of the Helmholtz Association of German Research Centers. www.mdc-berlin.de